JPMorgan Starts Kythera Biopharmaceuticals (KYTH) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
Go back to JPMorgan Starts Kythera Biopharmaceuticals (KYTH) at Overweight
November 5, 2012 9:11 AM EST
Goldman Sachs initiates coverage on Kythera Biopharmaceuticals (NASDAQ: KYTH) with a Neutral. PT $23.00.
The analyst comments: "Kythera's story is driven by ATX-101, a first-in-class injectable product for localized fat reduction that we believe holds both a high likelihood of achieving FDA approval and... More
November 5, 2012 8:48 AM EST
Leerink Swann initiates coverage on Kythera Biopharmaceuticals (NASDAQ: KYTH) with a Outperform. PT $28.00.
The firm comments: "We recommend purchase of KYTH based on (1) compelling prospects for clinical and regulatory success in the US and Europe for a first-inclass product (ATX-101) for the treatment of... More
November 5, 2012 8:43 AM EST
Lazard Capital initiates coverage on Kythera Biopharmaceuticals (NASDAQ: KYTH) with a Buy. PT $32.00.
For an analyst ratings summary and ratings history on Kythera Biopharmaceuticals click here. For more ratings news on Kythera Biopharmaceuticals click here.
Shares of Kythera Biopharmaceuticals closed at $22.11 yesterday, with a 52 week range of $18.49-$25.30.... More
